The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

SU2C establishes $3.25M head and neck cancer research team

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Stand Up To Cancer announced the Stand Up To Cancer–Fanconi Anemia Research Fund–Farrah Fawcett Foundation Head and Neck Cancer Research Team, which will focus on new approaches to address head and neck squamous cell carcinoma, with an emphasis on cancers related to the human papillomavirus and Fanconi anemia.

The team has been awarded $3.25 million over three years to advance therapies, support new approaches, and improve patient outcomes for head and neck cancers. The team will receive $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation. The American Head and Neck Society and the Head and Neck Cancer Alliance also each provided $125,000 in support. 

Agata Smogorzewska, associate professor at The Rockefeller University, will lead the research team and Barbara Burtness, professor of medicine, interim associate director for diversity, equity and inclusion and co-leader, Developmental Therapeutics Program at Yale Cancer Center and Smilow Cancer Hospital, will serve as co-leader.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account